LPTX Stock Risk & Deep Value Analysis
LPTX
Healthcare โข Biotechnology
DVR Score
out of 10
The Bottom Line on LPTX
We analyzed LPTX using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LPTX through our deep value framework โ analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
๐LPTX Performance Overview3yr weekly
Unlock LPTX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close ยท Quarterly revenue & EPS ยท DVR score history
LPTX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
About LPTX (LPTX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$62.88M
LPTX Deep Value Analysis
LPTX Red Flags & Warning Signs
- โ
Negative or inconclusive DKN-01 clinical trial results (Q2/Q3 2026)
- โ
Failure to secure adequate financing, leading to further significant dilution or operational slowdowns
- โ
Regulatory delays or adverse outcomes for DKN-01
Unlock LPTX Red Flags & Risk Warnings
Create a free account to see the full analysis
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
LPTX Financial Health Metrics
Market Cap
$62.88M
LPTX Competitive Moat Analysis
Sign in to unlockMoat Rating
None
Moat Trend
Stable
Moat Sources
1 Identified
The primary potential 'moat' lies solely in the intellectual property (patents) surrounding DKN-01. However, this IP does not constitute a durable moat until the drug demonstrates significant clinical efficacy and receives regulatory approval, establishing a clear market advantage and competitive barrier. Without this, the IP alone offers limited protection.
LPTX Competitive Moat Analysis
Sign up to see competitive advantages
LPTX Catalysts & Growth Drivers
Near-Term (0-6 months)
- โขDKN-01 Phase 2 clinical data readout for Gastric/GEJ Cancer (Expected Q2/Q3 2026)
- โขUpdates on financing activities and cash runway extension (Ongoing)
Medium-Term (6-18 months)
- โขPotential initiation of Phase 3 trials for DKN-01 (Dependent on Phase 2 success)
- โขExpanded strategic partnerships or licensing agreements for DKN-01 outside current territories
Long-Term (18+ months)
- โขRegulatory submission and potential approval of DKN-01 in target indications
- โขPipeline expansion with new preclinical or early-stage assets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
LPTX Bull Case: What Could Go Right
- โ
Clear, positive efficacy and safety data from DKN-01 Phase 2 trials
- โ
Successful non-dilutive financing or significant partnership milestones
- โ
Increased institutional ownership or analyst upgrades post-catalyst
Bull Case Analysis
See what could go right with Premium
Never miss a move on LPTX
Create a free account to set price alerts and get notified on Telegram when LPTX hits your targets.
๐ Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for LPTX (LPTX)?
As of March 15, 2026, LPTX has a DVR Score of 2.6 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of LPTX?
LPTX's market capitalization is approximately $62.9M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does LPTX use?
LPTX is the ticker symbol for LPTX. The company trades on the NCM.
What is the risk level for LPTX stock?
Our analysis rates LPTX's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the LPTX DVR analysis updated?
Our AI-powered analysis of LPTX is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.
Important Disclaimer โ Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.